Skip to main content
LISATA THERAPEUTICS, INC. logo

LISATA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · LSTA ISIN · US1280583022 LEI · 5493002287F62M3EGQ04 US Manufacturing
Open in API
Filings indexed 1,093 across all filing types
Latest filing 2020-11-17 Board/Management Inform…
Country US United States of America
Listing US LSTA

About LISATA THERAPEUTICS, INC.

https://www.lisata.com/

Lisata Therapeutics is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for advanced solid tumors and other major diseases. The company's core technology is the proprietary CendR Platform®, designed to enhance the targeted, tissue-penetrating delivery of anti-cancer drugs to solid tumors. The platform also aims to target non-cancerous, immunosuppressive cells within the tumor microenvironment, seeking to improve the efficacy of a patient's immune system and immunotherapies in fighting cancer.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated November 17, 2020. The content specifically announces the resignation of a key executive, Dr. Douglas W. Losordo, including his positions and effective date of resignation. There is no financial data or discussion of financial results, nor is it a report or presentation. The primary focus is on a change in senior management. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document length is 3428 characters, which is consistent with a typical 8-K announcement of management changes. Therefore, the appropriate classification is MANG with high confidence.
2020-11-17 English
10-Q
Interim / Quarterly Report 9M 2020
2020-11-05 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 1, 2020, by Caladrius Biosciences, Inc. It includes an Item 2.02 Results of Operations and Financial Condition, referencing financial results, and Item 7.01 Regulation FD Disclosure which includes a press release regarding earnings release dated November 5, 2020. The document also mentions a conference call to review financial results. The presence of an earnings release press release and a conference call announcement strongly indicates this is an Earnings Release filing. The document length (6388 characters) is sufficient to contain substantive information beyond a mere announcement, and it includes details about director appointment and financial results disclosure, but the primary financial disclosure is the earnings release. Therefore, the best classification is Earnings Release (ER).
2020-11-05 English
FORM 4
Director's Dealing
2020-11-03 English
FORM 3
Director's Dealing
2020-11-03 English
FORM 4
Director's Dealing
2020-09-10 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.